1 |
Scheen, A. J., Finer, N., Hollander, P., Jensen, M. D. and Van Gaal, L. F. for the RIO-Diabetes Study Group. (2006). Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet 368, 1660-1672.
DOI
ScienceOn
|
2 |
Sjostrom, L., Narbro, K., Sjostrom, C.D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., Bengtsson, C., Dahlgren, S., Gummesson, A., Jacobson, P., Karlsson, J., Lindroos, A. K., Lonroth, H., Naslund, I., Olbers, T., Stenlof, K., Torgerson, J., Agren, G. and Carlsson, L. M. S. for the Swedish Obese Subjects Study. (2007). Effects of bariatric surgery on mortality in Swedish obese subjects. N. Engl. J. Med., 357, 741-752.
DOI
ScienceOn
|
3 |
Sjostrom, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P. and Krempf, M. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group Lancet 352, 167-172.
DOI
ScienceOn
|
4 |
Torgerson, J. S., Hauptman, J., Boldrin, M. N. and Sjöström, L. (2004). XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27, 155-161.
DOI
ScienceOn
|
5 |
W.H.O. Expert Consultation. (2004). Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157-163.
DOI
ScienceOn
|
6 |
Yusuf, S., Hawken, S., Ounpuu, S., Bautista, L., Franzosi, M. G., Commerford, P., Lang, C. C., Rumboldt, Z., Onen, C. L., Lisheng, L., Tanomsup, S., Wangai P., Razak, F., Sharma, A. M. and Anand, S. S. on behalf of the INTERHEART Study Investigators. (2005). Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study. Lancet 366, 1640-1649.
DOI
ScienceOn
|
7 |
Hauner, H., Meier, M., Wendland, G., Kurscheid T., Lauterbach, K. and S.A.T. Study Group. (2004). Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study. Exp. Clin. Endocrinol. Diabetes 112, 201-207.
DOI
ScienceOn
|
8 |
Heusser, K., Tank, J., Diedrich, A., Engeli, S., Klaua, S., Krüger, N., Strauss, A., Stoffels, G., Luft, F. C. and Jordan, J. (2006). Influence of sibutramine treatment on sympathetic vasomotor tone in obese subjects. Clin. Pharmacol. Ther., 79, 500-508.
DOI
ScienceOn
|
9 |
James, W. P. T., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rössner, S., Saris, W. H. M. and Van Gaal, L. F. for the STORM Study Group. (2000). Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 356, 2119-2125.
DOI
ScienceOn
|
10 |
McNulty, S. J., Ur, E. and Williams, G. for The Multicenter Sibutramine Study Group. (2003). A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26, 125-131.
DOI
ScienceOn
|
11 |
Neal, B., Chapman, N. and Patel, A. (2002). Managing the global burden of cardiovascular disease. Eur. Heart J., 4 (Suppl F), F2-F6.
DOI
ScienceOn
|
12 |
Padwal, R. S. and Majumdar, S. R. (2007). Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369, 71-77.
DOI
ScienceOn
|
13 |
Prospective Studies Collaboration. (2009). Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 373, 1083-1096.
DOI
ScienceOn
|
14 |
Birkenfeld, A. L., Schroeder, C., Boschmann, M., Tank, J., Franke, G., Luft, F. C., Biaggioni, I., Sharma, A. M. and Jordan, J. (2002). Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106, 2459-2465.
DOI
ScienceOn
|
15 |
Guerciolini, R. (1997). Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord. 21(Suppl 3), S12-23.
|
16 |
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H. and Astrup, A. (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370, 1706-1713.
DOI
ScienceOn
|
17 |
Després, J. P., Golay, A. and Sjöström, L. for the Rimonabant in Obesity-Lipids Study Group. (2005). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 353, 2121-2134.
DOI
ScienceOn
|
18 |
Eriksson, K. F. and Lindgarde, F. (1998). No excess 12-year mortality in men with impaired glucose tolerance who participated in the Malmo Preventive Trial with diet and exercise. Diabetologia 41, 1010-1016.
DOI
|
19 |
Halford, J. C. G., Boyland, E. J., Cooper, S. J., Dovey, T. M., Huda, M. S. B., Dourish, C. T., Dawson, G. R. and Wilding, J. P. H. (2008). The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women. J. Psychopharmacology 1-11 (e-pub ahead of print).
DOI
ScienceOn
|
20 |
Huxley, R., James, W. P., Barzi, F., Patel, J.V., Lear, S. A., Suriyawongpaisal, P., Janus E, Caterson, I., Zimmet, P., Prabhakaran, D., Reddy, S., Woodward, M. and The Obesity in Asia Collaboration. (2008). Obes. Reviews 9, S1, 53-61.
DOI
ScienceOn
|
21 |
Orexigen Company Press Release. (2009). Available at: http://ir.orexigen.com/phoenix.zhtml?c=207034&p=irolnewsArticle&ID=1308920&highlight=obesity.
|
22 |
Cota, D., Marsicano, G., Tschop, M., Grubler, Y., Flachskamm, C., Schubert, M., Auer, D., Yassouridis, A., Thone-Reineke, C., Ortmann, S., Tomassoni, F., Cervino, C., Nisoli, E., Linthorst, A. C. E., Pasquali, R., Lutz, B., Stalla, G. K. and Pagotto, U. (2003). The endogenous cannabinoid system affects energy balance via central orixegenic drive and peripheral lipogenesis. J. Clin. Invest. 112, 423-431.
DOI
|
23 |
Walsh, K. M., Leen, E. and Lean, M.E. (1999). The effect of sibutramine on resting energy expenditure and adrenalineinduced thermogenesis in obese females. Int. J. Obes. Relat. Metab. Disord., 23, 1009-1015.
DOI
ScienceOn
|
24 |
F.D.A. U.S. Food and Drug Administration Center for Drug Evaluation and Research. (1997). F.D.A. Analysis of Cardiac Valvular Dysfunction with Use of Appetite Suppressants. Available: http://www.fda.gov/cder/news/slides/index.htm [1997, Sep 17].
|
25 |
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Devin, J. and Rosenstock, J. for the RIO-North America Study Group. (2006). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients - RIO-North America: a randomized controlled trial. J. Am. Med. Assoc., 295, 761-775.
DOI
ScienceOn
|
26 |
Yusuf, S., Hawken, S., Ounpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J. and Lisheng, L. on behalf of the INTERHEART Study Investigators. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364 (9438), 937-952.
DOI
ScienceOn
|
27 |
Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, A. I. and Astrup, A. (1999). The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int. J. Obes. Relat. Metab. Disord., 23, 1016-1024.
DOI
ScienceOn
|
28 |
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., Murray, C. L. J., (Eds.). (2006). Global Burden of Disease and Risk Factors. New York. Oxford University Press.
|